APTAMIR
Dead / Abandoned — Abandoned — no statement of use filed (as of 08 May 2023)
What this means for you
This application is over — abandoned 08 May 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88356988
- Mark type
- Design + words
- Filed
- 26 Mar 2019
- Published for opposition
- 11 Feb 2020
- Abandoned
- 08 May 2023
- Attorney of record
- Andrea K. Shannon
Goods and services
- Class 005 — Pharmaceuticals: Medicinal and biological preparations for pharmaceutical, clinical or medical treatment, namely, preparations for the modulation of gene and protein expression working at DNA transcription, RNA translation and/or degradation processes related thereto for the treatment of cardiovascular diseases, metabolic diseases, overweight, obesity, diabetes mellitus, dyslipidemia, liver steatosis (fatty liver disease), steatohepatitis, non-alcoholic fatty liver disease, atherosclerosis, and chronic visceral inflammation
Owner
- AptamiR Therapeutics, Inc, Naples, FL, US
- AptamiR Therapeutics, Inc, Nap, FL, US
Prosecution history
- 08 May 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 08 May 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 13 Oct 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Oct 2022 — SOU EXTENSION 5 GRANTED
- 04 Oct 2022 — SOU EXTENSION 5 FILED
- 12 Oct 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 04 Oct 2022 — SOU TEAS EXTENSION RECEIVED
- 05 Apr 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Apr 2022 — SOU EXTENSION 4 GRANTED
- 01 Apr 2022 — SOU EXTENSION 4 FILED
- 01 Apr 2022 — SOU TEAS EXTENSION RECEIVED
- 02 Oct 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 Sept 2021 — SOU EXTENSION 3 GRANTED
- 30 Sept 2021 — SOU EXTENSION 3 FILED
- 30 Sept 2021 — SOU TEAS EXTENSION RECEIVED